See more : JBB Builders International Limited (1903.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Kolon TissueGene, Inc. (950160.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kolon TissueGene, Inc., a leading company in the industry within the sector.
You may be interested
- THG Plc (THGHY) Income Statement Analysis – Financial Results
- ImmunoGen, Inc. (IMU.DE) Income Statement Analysis – Financial Results
- Caeneus Minerals Ltd (CAD.AX) Income Statement Analysis – Financial Results
- Strategic Global Investments, Inc. (STBV) Income Statement Analysis – Financial Results
- SunLink Health Systems, Inc. (SSY) Income Statement Analysis – Financial Results
Kolon TissueGene, Inc. (950160.KQ)
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 3.71B | 9.46B | 4.00B | 3.56B | 3.03B |
| Cost of Revenue | 3.29B | 1.77B | 3.56B | 3.18B | 2.79B |
| Gross Profit | 413.21M | 7.69B | 438.28M | 376.92M | 240.37M |
| Gross Profit Ratio | 11.15% | 81.33% | 10.95% | 10.60% | 7.92% |
| Research & Development | 5.64B | 7.12B | 29.89B | 15.72B | 19.09B |
| General & Administrative | 8.42B | 9.49B | 10.61B | 18.55B | 17.62B |
| Selling & Marketing | 514.12M | 453.18M | 539.87M | 795.55M | 1.55B |
| SG&A | 8.93B | 9.94B | 11.15B | 19.34B | 19.17B |
| Other Expenses | 6.35B | 4.68B | 249.99M | -79.74M | 7.15B |
| Operating Expenses | 20.92B | 23.99B | 47.34B | 41.93B | 45.42B |
| Cost & Expenses | 24.21B | 25.76B | 50.91B | 45.11B | 48.21B |
| Interest Income | 2.22B | 670.49M | 129.69M | 876.57M | 2.41B |
| Interest Expense | 285.82M | 371.18M | 466.46M | 835.26M | 1.18B |
| Depreciation & Amortization | 1.41B | 1.66B | 1.55B | 1.64B | 1.29B |
| EBITDA | -15.27B | -7.78B | -45.13B | -39.19B | -47.47B |
| EBITDA Ratio | -412.13% | -82.27% | -1,122.15% | -1,102.05% | -1,564.15% |
| Operating Income | -20.50B | -16.30B | -46.90B | -41.56B | -45.18B |
| Operating Income Ratio | -553.26% | -172.41% | -1,171.65% | -1,168.68% | -1,488.63% |
| Total Other Income/Expenses | 3.53B | 6.48B | -248.39M | -108.45M | -4.76B |
| Income Before Tax | -16.97B | -9.82B | -47.15B | -41.66B | -49.94B |
| Income Before Tax Ratio | -457.93% | -103.86% | -1,177.86% | -1,171.73% | -1,645.46% |
| Income Tax Expense | 253.15M | 1.32B | 218.27M | 123.68M | 51.77M |
| Net Income | -17.22B | -11.14B | -47.37B | -41.79B | -49.99B |
| Net Income Ratio | -464.76% | -117.77% | -1,183.31% | -1,175.21% | -1,647.16% |
| EPS | -240.20 | -168.00 | -773.60 | -684.40 | -818.20 |
| EPS Diluted | -240.20 | -168.00 | -773.60 | -684.40 | -818.20 |
| Weighted Avg Shares Out | 71.71M | 66.29M | 61.23M | 61.06M | 61.10M |
| Weighted Avg Shares Out (Dil) | 71.71M | 66.29M | 61.23M | 61.06M | 61.10M |
No news found for: 950160.KQ
Source: https://incomestatements.info
Category: Stock Reports